Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

John R. David, M.D.

TitleProfessor of Medicine
InstitutionBrigham and Women's Hospital
DepartmentMedicine
AddressHarvard School of Public Health
Bldg 1
665 Huntington Ave
Boston MA 02115
Fax617/738-4914
Other Positions
TitleRichard Pearson Strong Professor of Tropical Public Health in the Faculty of Public Health, Emeritus
InstitutionHarvard School of Public Health
DepartmentImmunology and Infectious Diseases


 Mentoring 
 completed student projects
The Effects of Deltamethrin PVC Canine Collars on Leismaniasis Control in Baturite, Brasil
International, 06/19/00 - 08/25/00

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Wilson ME, Fregni F, de S M Veras MA, Dyett J, Shei A, Ribeiro GS, David J, Castro MC, Segurado AC, Ko AI, Reis MG. Collaborative teaching and learning: a model for building capacity and partnerships to address NTDs. PLoS Negl Trop Dis. 2011; 5(3):e939.
    View in: PubMed
  2. Wang B, Huang X, Wolters PJ, Sun J, Kitamoto S, Yang M, Riese R, Leng L, Chapman HA, Finn PW, David JR, Bucala R, Shi GP. Cutting edge: Deficiency of macrophage migration inhibitory factor impairs murine airway allergic responses. J Immunol. 2006 Nov 1; 177(9):5779-84.
    View in: PubMed
  3. Werneck GL, Costa CH, Walker AM, David JR, Wand M, Maguire JH. Multilevel modelling of the incidence of visceral leishmaniasis in Teresina, Brazil. Epidemiol Infect. 2007 Feb; 135(2):195-201.
    View in: PubMed
  4. McDevitt MA, Xie J, Shanmugasundaram G, Griffith J, Liu A, McDonald C, Thuma P, Gordeuk VR, Metz CN, Mitchell R, Keefer J, David J, Leng L, Bucala R. A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J Exp Med. 2006 May 15; 203(5):1185-96.
    View in: PubMed
  5. Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK, Santos LL, Morand EF, David JR, Koch AE. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis. Arthritis Res Ther. 2006; 8(4):R132.
    View in: PubMed
  6. Gomes RN, Castro-Faria-Neto HC, Bozza PT, Soares MB, Shoemaker CB, David JR, Bozza MT. Calcitonin gene-related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia. Shock. 2005 Dec; 24(6):590-4.
    View in: PubMed
  7. Lobo IM, Soares MB, Correia TM, de Freitas LA, Oliveira MI, Nakatani M, Netto E, Badaro R, David JR. Heat therapy for cutaneous leishmaniasis elicits a systemic cytokine response similar to that of antimonial (Glucantime) therapy. Trans R Soc Trop Med Hyg. 2006 Jul; 100(7):642-9.
    View in: PubMed
  8. Rice EK, Nikolic-Paterson DJ, David JR, Bucala R, Metz CN, Atkins RC, Tesch GH. Macrophage accumulation and renal fibrosis are independent of macrophage migration inhibitory factor in mouse obstructive nephropathy. Nephrology (Carlton). 2004 Oct; 9(5):278-87.
    View in: PubMed
  9. Gregory JL, Leech MT, David JR, Yang YH, Dacumos A, Hickey MJ. Reduced leukocyte-endothelial cell interactions in the inflamed microcirculation of macrophage migration inhibitory factor-deficient mice. Arthritis Rheum. 2004 Sep; 50(9):3023-34.
    View in: PubMed
  10. Pan JH, Sukhova GK, Yang JT, Wang B, Xie T, Fu H, Zhang Y, Satoskar AR, David JR, Metz CN, Bucala R, Fang K, Simon DI, Chapman HA, Libby P, Shi GP. Macrophage migration inhibitory factor deficiency impairs atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation. 2004 Jun 29; 109(25):3149-53.
    View in: PubMed
  11. dos-Santos WL, David J, Badaró R, de-Freitas LA. Association between skin parasitism and a granulomatous inflammatory pattern in canine visceral leishmaniosis. Parasitol Res. 2004 Jan; 92(2):89-94.
    View in: PubMed
  12. Jose MD, David JR, Atkins RC, Chadban SJ. Blockade of macrophage migration inhibitory factor does not prevent acute renal allograft rejection. Am J Transplant. 2003 Sep; 3(9):1099-106.
    View in: PubMed
  13. Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, David JR, Bucala R, Morand EF. Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum. 2003 Jul; 48(7):1881-9.
    View in: PubMed
  14. Rodríguez-Sosa M, Satoskar AR, David JR, Terrazas LI. Altered T helper responses in CD40 and interleukin-12 deficient mice reveal a critical role for Th1 responses in eliminating the helminth parasite Taenia crassiceps. Int J Parasitol. 2003 Jul; 33(7):703-11.
    View in: PubMed
  15. Rodríguez-Sosa M, Rosas LE, David JR, Bojalil R, Satoskar AR, Terrazas LI. Macrophage migration inhibitory factor plays a critical role in mediating protection against the helminth parasite Taenia crassiceps. Infect Immun. 2003 Mar; 71(3):1247-54.
    View in: PubMed
  16. Koebernick H, Grode L, David JR, Rohde W, Rolph MS, Mittrücker HW, Kaufmann SH. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc Natl Acad Sci U S A. 2002 Oct 15; 99(21):13681-6.
    View in: PubMed
  17. Werneck GL, Costa CH, Walker AM, David JR, Wand M, Maguire JH. The urban spread of visceral leishmaniasis: clues from spatial analysis. Epidemiology. 2002 May; 13(3):364-7.
    View in: PubMed
  18. Rodriguez-Sosa M, David JR, Bojalil R, Satoskar AR, Terrazas LI. Cutting edge: susceptibility to the larval stage of the helminth parasite Taenia crassiceps is mediated by Th2 response induced via STAT6 signaling. J Immunol. 2002 Apr 1; 168(7):3135-9.
    View in: PubMed
  19. Costa CH, Stewart JM, Gomes RB, Garcez LM, Ramos PK, Bozza M, Satoskar A, Dissanayake S, Santos RS, Silva MR, Shaw JJ, David JR, Maguire JH. Asymptomatic human carriers of Leishmania chagasi. Am J Trop Med Hyg. 2002 Apr; 66(4):334-7.
    View in: PubMed
  20. Mitchell RA, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J, Bucala R. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A. 2002 Jan 8; 99(1):345-50.
    View in: PubMed
  21. de Jong YP, Abadia-Molina AC, Satoskar AR, Clarke K, Rietdijk ST, Faubion WA, Mizoguchi E, Metz CN, Alsahli M, ten Hove T, Keates AC, Lubetsky JB, Farrell RJ, Michetti P, van Deventer SJ, Lolis E, David JR, Bhan AK, Terhorst C, Sahli MA. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol. 2001 Nov; 2(11):1061-6.
    View in: PubMed
  22. David JR, Stamm LM, Bezerra HS, Souza RN, Killick-Kendrick R, Lima JW. Deltamethrin-impregnated dog collars have a potent anti-feeding and insecticidal effect on Lutzomyia longipalpis and Lutzomyia migonei. Mem Inst Oswaldo Cruz. 2001 Aug; 96(6):839-47.
    View in: PubMed
  23. Satoskar AR, Bozza M, Rodriguez Sosa M, Lin G, David JR. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect Immun. 2001 Feb; 69(2):906-11.
    View in: PubMed
  24. Monteforte GM, Takeda K, Rodriguez-Sosa M, Akira S, David JR, Satoskar AR. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol. 2000 Jun 1; 164(11):5890-3.
    View in: PubMed
  25. Satoskar AR, Rodig S, Telford SR, Satoskar AA, Ghosh SK, von Lichtenberg F, David JR. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology. Eur J Immunol. 2000 Mar; 30(3):834-9.
    View in: PubMed
  26. Satoskar AR, Stamm LM, Zhang X, Okano M, David JR, Terhorst C, Wang B. NK cell-deficient mice develop a Th1-like response but fail to mount an efficient antigen-specific IgG2a antibody response. J Immunol. 1999 Nov 15; 163(10):5298-302.
    View in: PubMed
  27. Stamm LM, Satoskar AA, Ghosh SK, David JR, Satoskar AR. STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis. Eur J Immunol. 1999 Aug; 29(8):2524-9.
    View in: PubMed
  28. Satoskar AR, Stamm LM, Zhang X, Satoskar AA, Okano M, Terhorst C, David JR, Wang B. Mice lacking NK cells develop an efficient Th1 response and control cutaneous Leishmania major infection. J Immunol. 1999 Jun 1; 162(11):6747-54.
    View in: PubMed
  29. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C, David JR. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med. 1999 Jan 18; 189(2):341-6.
    View in: PubMed
  30. Stamm LM, Räisänen-Sokolowski A, Okano M, Russell ME, David JR, Satoskar AR. Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis. J Immunol. 1998 Dec 1; 161(11):6180-8.
    View in: PubMed
  31. Bozza M, Soares MB, Bozza PT, Satoskar AR, Diacovo TG, Brombacher F, Titus RG, Shoemaker CB, David JR. The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur J Immunol. 1998 Oct; 28(10):3120-7.
    View in: PubMed
  32. Ashford DA, David JR, Freire M, David R, Sherlock I, Eulálio MC, Sampaio DP, Badaro R. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg. 1998 Jul; 59(1):53-7.
    View in: PubMed
  33. Satoskar AR, Okano M, Connaughton S, Raisanen-Sokolwski A, David JR, Labow M. Enhanced Th2-like responses in IL-1 type 1 receptor-deficient mice. Eur J Immunol. 1998 Jul; 28(7):2066-74.
    View in: PubMed
  34. Soares MB, Titus RG, Shoemaker CB, David JR, Bozza M. The vasoactive peptide maxadilan from sand fly saliva inhibits TNF-alpha and induces IL-6 by mouse macrophages through interaction with the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor. J Immunol. 1998 Feb 15; 160(4):1811-6.
    View in: PubMed
  35. Satoskar A, Okano M, David JR. Gammadelta T cells are not essential for control of cutaneous Leishmania major infection in genetically resistant C57BL/6 mice. J Infect Dis. 1997 Dec; 176(6):1649-52.
    View in: PubMed
  36. Soares MB, David JR, Titus RG. An in vitro model for infection with Leishmania major that mimics the immune response in mice. Infect Immun. 1997 Jul; 65(7):2837-45.
    View in: PubMed
  37. Secor WE, del Corral H, dos Reis MG, Ramos EA, Zimon AE, Matos EP, Reis EA, do Carmo TM, Hirayama K, David RA, David JR, Harn DA. Association of hepatosplenic schistosomiasis with HLA-DQB1*0201. J Infect Dis. 1996 Nov; 174(5):1131-5.
    View in: PubMed
  38. Bozza M, Kolakowski LF, Jenkins NA, Gilbert DJ, Copeland NG, David JR, Gerard C. Structural characterization and chromosomal location of the mouse macrophage migration inhibitory factor gene and pseudogenes. Genomics. 1995 Jun 10; 27(3):412-9.
    View in: PubMed
  39. David JR. MIF as a GST. Parasitol Today. 1993 Sep; 9(9):315-6.
    View in: PubMed
  40. Badaro R, Eulalio MC, Benson D, Freire M, Miranda JC, Pedral-Sampaio D, Burns JM, David JR, Johnson WD, Reed SG. Sensitivity and specificity of a recombinant Leishmania chagasi antigen in the serodiagnosis of visceral leishmaniasis. Arch Inst Pasteur Tunis. 1993 Jul-Oct; 70(3-4):331-2.
    View in: PubMed
  41. Ashford DA, Badaro R, Eulalio C, Freire M, Miranda C, Zalis MG, David JR. Studies on the control of visceral leishmaniasis: validation of the Falcon assay screening test--enzyme-linked immunosorbent assay (FAST-ELISA) for field diagnosis of canine visceral leishmaniasis. Am J Trop Med Hyg. 1993 Jan; 48(1):1-8.
    View in: PubMed
  42. Weiser WY, Pozzi LM, Titus RG, David JR. Recombinant human migration inhibitory factor has adjuvant activity. Proc Natl Acad Sci U S A. 1992 Sep 1; 89(17):8049-52.
    View in: PubMed
  43. Weiser WY, Pozzi LM, David JR. Human recombinant migration inhibitory factor activates human macrophages to kill Leishmania donovani. J Immunol. 1991 Sep 15; 147(6):2006-11.
    View in: PubMed
  44. David JR. The citizen-scientist: an essential species for our times. Am J Trop Med Hyg. 1991 Mar; 44(3):235-43.
    View in: PubMed
  45. Kahl LP, Byram JE, David JR, Comerford SA, Von Lichtenberg F. Leishmania (Viannia) braziliensis: comparative pathology of golden hamsters infected with isolates from cutaneous and mucosal lesions of patients residing in Tres Bracos, Bahia, Brazil. Am J Trop Med Hyg. 1991 Feb; 44(2):218-32.
    View in: PubMed
  46. Kahl LP, Byram JE, David JR. Leishmania (Viannia) braziliensis isolated from cutaneous and mucosal lesions of patients residing in Tres Bracos, Bahia, Brazil differ in virulence for the golden hamster. Trans R Soc Trop Med Hyg. 1990 Nov-Dec; 84(6):783-4.
    View in: PubMed
  47. Silberstein DS, David JR, Harn DA. The ability of mouse monoclonal antibodies to direct the cytotoxic function of cytokine-activated human eosinophils. Hybridoma. 1990 Jun; 9(3):237-42.
    View in: PubMed
  48. Stein LD, Harn DA, David JR. A cloned ATP:guanidino kinase in the trematode Schistosoma mansoni has a novel duplicated structure. J Biol Chem. 1990 Apr 25; 265(12):6582-8.
    View in: PubMed
  49. Silberstein DS, Minkoff MS, Creasey AA, David JR. A serum factor that suppresses the cytotoxic function of cytokine-stimulated human eosinophils. J Exp Med. 1990 Mar 1; 171(3):681-93.
    View in: PubMed
  50. Weiser WY, Temple PA, Witek-Giannotti JS, Remold HG, Clark SC, David JR. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. Proc Natl Acad Sci U S A. 1989 Oct; 86(19):7522-6.
    View in: PubMed
  51. Barker RH, Brandling-Bennett AD, Koech DK, Mugambi M, Khan B, David R, David JR, Wirth DF. Plasmodium falciparum: DNA probe diagnosis of malaria in Kenya. Exp Parasitol. 1989 Oct; 69(3):226-33.
    View in: PubMed
  52. Silberstein DS, Ali MH, Baker SL, David JR. Human eosinophil cytotoxicity-enhancing factor. Purification, physical characteristics, and partial amino acid sequence of an active polypeptide. J Immunol. 1989 Aug 1; 143(3):979-83.
    View in: PubMed
  53. Silberstein DS, Schoof DD, Rodrick ML, Tai PC, Spry CJ, David JR, Eberlein TJ. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J Immunol. 1989 Mar 15; 142(6):2162-7.
    View in: PubMed
  54. Patel RJ, Piessens WF, David JR, Wirth DF. A cloned DNA fragment for identification of Mycobacterium tuberculosis. Rev Infect Dis. 1989 Mar-Apr; 11 Suppl 2:S411-9.
    View in: PubMed
  55. Van Niel A, Zacks SE, David JR, Remold HG, Weiser WY. Identification and characterization of a non-interferon antileishmanial macrophage activating factor (antileishmanial MAF). Adv Exp Med Biol. 1988; 239:231-7.
    View in: PubMed
  56. Weiser WY, Van Niel A, Clark SC, David JR, Remold HG. Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med. 1987 Nov 1; 166(5):1436-46.
    View in: PubMed
  57. Rocklin RE, Winston CT, David JR. Activation of human blood monocytes by products of sensitized lymphocytes. J Clin Invest. 1974 Feb; 53(2):559-64.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu. SPH faculty should contact Maria Maxell (mmaxellhsph.harvard.edu).
David's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (352) concept(s)
_
Co-Authors
See all (20) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_